BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• FDA

  FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma

  Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.

  May 27, 2022

   · 

  13 min read
• PreveCeutical Announces Change in Directors and Investor Awareness Services

  Mr. Keith Anderson and Mr. Mark Lotz will be stepping down as directors of the Company effective May 31, 2022, to allow them more time to focus on their business.

  May 27, 2022

   · 

  5 min read
• Bio NC

  Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 27, 2022

  Milestone Pharmaceuticals Inc. announced that Milestone’s Compensation Committee granted three new employees incentive stock options to purchase an aggregate of 92,000 common shares, at a per share exercise price of $5.48, the closing price of Milestone’s common stock on May 16, 2022.

  May 27, 2022

   · 

  1 min read
• Business

  KDx Diagnostics Inc. and UroGPO Announce a Partnership to Offer the URO17® NON-INVASIVE Urine Test for Bladder Cancer in the United States

  KDx Diagnostics and UroGPO announced today the partnership to provide the URO17® test (Research Use Only in the US) for the detection of bladder cancer.

  May 27, 2022

   · 

  3 min read